While reinforcing cell cycle arrest, rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts

Sunlight predisposes to skin cancer and melanomas. Ultraviolet A (UVA), a long wave component of sunlight, can reach dermal fibroblasts. Here we studied UVA-induced senescence in human fibroblasts in vitro. It is known that senescence occurs, when cell cycle is arrested, but mTOR is still active, thus converting arrest to senescence (geroconversion). We showed that, while arresting cell cycle, UVA did not inhibit mTOR, enabling geroconversion. In UVA-treated cells, mTOR remained fully active. Rapamycin and Torins 1/ 2 prevented UVA-induced senescent phenotype, although they further re-enforced cell cycle arrest. Given that senescent stromal fibroblasts support tumorigenesis, we envision that mTOR inhibitors may potentially be used to prevent sunlight-caused tumors as well as skin photo-aging.

• Publication year

  2017

• Venue

  OncoTarget

• Publication date

  2017-05-11

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.18632/oncotarget.17827PMID 29312653PMCID 5752566
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapamycin reverses the senescent phenotype and improves immuno-regulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway

  2016cited by this paper
• Reversal of phenotypes of cellular senescence by pan-mTOR inhibition

  2016cited by this paper
• Evidence that hematopoietic stem cell function is preserved during aging in long-lived S6K1 mutant mice

  2016cited by this paper
• Gerosuppression by pan-mTOR inhibitors

  2016cited by this paper
• Association of Sirolimus Use With Risk for Skin Cancer in a Mixed-Organ Cohort of Solid-Organ Transplant Recipients With a History of Cancer.

  2016cited by this paper
• Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program)

  2015cited by this paper
• p53 and rapamycin are additive

  2015cited by this paper
• Dual mTORC1/C2 inhibitors: gerosuppressors with potential anti-aging effect

  2015cited by this paper
• Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin

  2014cited by this paper
• Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion

  2014cited by this paper
• Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data

  2014cited by this paper
• Geroconversion: irreversible step to cellular senescence

  2014influential reference
• Non‐melanoma skin cancer is reduced after switch of immunosuppression to mTOR‐inhibitors in organ transplant recipients

  2014cited by this paper
• Rapamycin Enhances Long-Term Hematopoietic Reconstitution of Ex Vivo Expanded Mouse Hematopoietic Stem Cells by Inhibiting Senescence

  2014cited by this paper
• Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program

  2014cited by this paper
• Senescence regulation by mTOR.

  2013cited by this paper
• Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors

  2013cited by this paper
• Cellular senescence and the senescent secretory phenotype: therapeutic opportunities.

  2013cited by this paper
• Hypoxia, MTOR and autophagy

  2013cited by this paper
• Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice

  2012cited by this paper
• Rapalogs in cancer prevention

  2012cited by this paper
• Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging

  2012cited by this paper
• New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis

  2012cited by this paper
• Shedding light on melanocyte pathobiology in vivo.

  2012cited by this paper
• Sirolimus and secondary skin-cancer prevention in kidney transplantation.

  2012cited by this paper
• Prospective study of ultraviolet radiation exposure and risk of cancer in the United States

  2012cited by this paper
• Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency

  2012cited by this paper
• Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling

  2012cited by this paper
• Transplantation: Sirolimus for secondary SCC prevention in renal transplantation

  2012cited by this paper
• Enteric-delivered rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence.

  2012cited by this paper
• Status of mTOR activity may phenotypically differentiate senescence and quiescence

  2012cited by this paper
• Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug.

  2012cited by this paper
• Hypoxia suppresses conversion from proliferative arrest to cellular senescence

  2012cited by this paper
• Rapamycin impairs UV induction of mutant‐p53 overexpressing cell clusters without affecting tumor onset

  2012cited by this paper
• mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis.

  2012cited by this paper
• Dissecting the role of mTOR complexes in cellular senescence

  2012cited by this paper
• Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial

  2011cited by this paper
• From growing to secreting: New roles for mTOR in aging cells

  2011cited by this paper
• Spatial Coupling of mTOR and Autophagy Augments Secretory Phenotypes

  2011cited by this paper
• Rapamycin Is a Potent Inhibitor of Skin Tumor Promotion by 12-O-Tetradecanoylphorbol-13-Acetate

  2011cited by this paper
• DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence

  2010cited by this paper
• Rapamycin extends maximal lifespan in cancer-prone mice.

  2010cited by this paper
• Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis

  2010cited by this paper
• Paradoxical suppression of cellular senescence by p53

  2010cited by this paper
• Weak p53 permits senescence during cell cycle arrest

  2010cited by this paper
• Interferon-γ links UV to melanocyte activation and promotes melanomagenesis

  2010cited by this paper
• An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*

  2009cited by this paper
• Rapamycin inhibits mTORC1, but not completely

  2009cited by this paper
• Growth stimulation leads to cellular senescence when the cell cycle is blocked

  2008cited by this paper
• Prevention of cancer by inhibiting aging

  2008cited by this paper
• Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice even with co-administration of cyclosporine A.

  2008cited by this paper
• Sirolimus: a potential chemopreventive agent.

  2008cited by this paper
• The gene expression profile of psoralen plus UVA-induced premature senescence in skin fibroblasts resembles a combined DNA-damage and stress-induced cellular senescence response phenotype.

  2007cited by this paper
• Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay.

  2007cited by this paper
• Identification of a Highly Effective Rapamycin Schedule that Markedly Reduces the Size, Multiplicity, and Phenotypic Progression of Tobacco Carcinogen–Induced Murine Lung Tumors

  2006cited by this paper
• Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.

  2006cited by this paper
• Sirolimus-induced remission of posttransplantation lymphoproliferative disorder.

  2006cited by this paper
• Sirolimus for Kaposi's sarcoma in renal-transplant recipients.

  2005cited by this paper
• Rapamycin: an anti-cancer immunosuppressant?

  2005cited by this paper
• Maintenance Immunosuppression with Target-of-Rapamycin Inhibitors is Associated with a Reduced Incidence of De Novo Malignancies

  2005cited by this paper
• Ultraviolet B but not Ultraviolet A Radiation Initiates Melanoma

  2004cited by this paper
• Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation

  2004cited by this paper
• Photoaging as a consequence of natural and therapeutic ultraviolet irradiation--studies on PUVA-induced senescence-like growth arrest of human dermal fibroblasts.

  2003cited by this paper
• Cell senescence and hypermitogenic arrest

  2003cited by this paper
• Cancer and aging: a model for the cancer promoting effects of the aging stroma.

  2002cited by this paper
• Psoralen plus UVA (PUVA) induced premature senescence as a model for stress-induced premature senescence.

  2002cited by this paper
• Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging

  2001cited by this paper
• Mutations in cancer genes of UV-induced skin tumors of hairless mice.

  1999cited by this paper
• Psoralen photoactivation promotes morphological and functional changes in fibroblasts in vitro reminiscent of cellular senescence.

  1998cited by this paper
• The role of cellular senescence in skin aging.

  1998cited by this paper
• UV‐induced skin cancer in a hairless mouse model

  1995cited by this paper

• Senotherapy: Implications for Transplantation.

  2025cites this paper
• Research progress on cell cycle arrest in dermal fibroblasts

  2025cites this paper
• Identifying ENO1 as a protein target of chlorogenic acid to inhibit cellular senescence and prevent skin photoaging in mice

  2024cites this paper
• The application of a multi‐component reaction peptide as a model regenerative active to enhance skin wound‐healing postlaser procedure in a double‐blinded placebo‐controlled clinical trial

  2023cites this paper
• Cellular aging and immunity

  2022cites this paper
• Improving the effectiveness of anti-aging modalities by using the constrained disorder principle-based management algorithms

  2022cites this paper
• Reversion of glucocorticoid-induced senescence and collagen synthesis decrease by LY294002 is mediated through p38 in skin

  2022cites this paper
• Hepatic Stellate Cell Senescence in Liver Fibrosis: Characteristics, Mechanisms and Perspectives.

  2021cites this paper
• The Role of Rapamycin in Healthspan Extension via the Delay of Organ Aging.

  2021cites this paper
• Targeted Senolytic Strategies Based on the Senescent Surfaceome

  2020cites this paper
• Senolytics in Disease, Ageing and Longevity

  2020cites this paper
• Correlative imaging of ionic transport and electronic structure in nano Li0.5FePO4 electrodes.

  2019cites this paper
• LncRNA RP11-670E13.6, interacted with hnRNPH, delays cellular senescence by sponging microRNA-663a in UVB damaged dermal fibroblasts

  2019cites this paper
• Cyanidin‐3‐o‐glucoside inhibits UVA‐induced human dermal fibroblast injury by upregulating autophagy

  2019cites this paper
• Rapamycin for the aging skin

  2019cites this paper
• Rapamycin retards epigenetic ageing of keratinocytes independently of its effects on replicative senescence, proliferation and differentiation

  2019cites this paper